<DOC>
	<DOC>NCT01697631</DOC>
	<brief_summary>This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with conventional Biphasic Human Insulin 30/70.</brief_summary>
	<brief_title>Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes Current treatment with conventional biphasic human insulin 30/70 b.i.d. (twice daily) for at least 3 months HbA1c (glycosylated haemoglobin) equal to or below 12% Willing and able to perform self blood glucose monitoring (SMBG) History of drug or alcohol dependence Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Previous participation in this trial Receipt of any investigational drug within the last month prior to this trial Known or suspected allergy to trial products or related products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>